ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "juvenile idiopathic arthritis (JIA) and tocilizumab"

  • Abstract Number: 1414 • 2018 ACR/ARHP Annual Meeting

    Pharmacovigilance of Biologics for Systemic Juvenile Idiopathic Arthritis Patients By the German Biologics Registry

    Gerd Horneff1, Gerd Ganser2, Toni Hospach3, Ivan Foeldvari4, Michael Borte5, Frank Weller-Heinemann6, Kirsten Minden7 and Ariane Klein8, 1Asklepios Kinderklinik St. Augustin GmbH, Sankt Augustin, Germany, 2Klinik für Kinder-und Jugendrheumatologie, Nordwestdeutsches Rheumazentrum, Sendenhorst, Germany, 3Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany, 4Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, 5St Georg Hospital, Leipzig, Germany, 6PRINTO, Genoa, Italy, 7Charité–Universitätsmedizin Berlin, Berlin, Germany, 8Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany

    Background/Purpose: Long-term surveillance of biologic drugs is particularly important in pediatric patients(pts). Since 2001, the German Biologics JIA Registry (BIKER) is allowing to follow up…
  • Abstract Number: 2425 • 2015 ACR/ARHP Annual Meeting

    Safety of Tocilizumab in Young Adults with Juvenile Idiopathic Arthritis (JIA)

    Jens Klotsche1, Martina Niewerth2, Johannes Peter Haas3, Angela Zink4, Gerd Horneff5 and Kirsten Minden6, 1Programme Area Epidemiology, German Rheumatism Research Center, a Leibniz institute, Berlin, Germany, 2Epidemiology, German Rheumatism Research Centre, Berlin, Germany, 3German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, 4Epidemiologie, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, 5Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 6Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany

    Background/Purpose: Tocilizumab was recently approved for the treatment of systemic JIA (sJIA) and polyarticular JIA (pJIA). Published data on the tolerability of tocilizumab in patients…
  • Abstract Number: 795 • 2013 ACR/ARHP Annual Meeting

    Second TNF-Inhibitor Or Alternative Biologic In Juvenile Idiopathic Arthritis (JIA) Patients Failing a First TNF-Inhibitor

    Kirsten Minden1, Klaus Tenbrock2, Gerd Horneff3 and Hans-Iko Huppertz4, 1Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, 2University Aachen, Aachen, Germany, 3Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 4Prof. Hess Childrens Hospital, Bremen, Germany

    Background/Purpose: Patients with incomplete response to initial anti-TNF treatment often are switched to other biologic treatments. However, little is known about the efficacy of switching…
  • Abstract Number: 272 • 2013 ACR/ARHP Annual Meeting

    Predictive Markers Of Joint Damages Of Children With Systemic-Onset Juvenile Idiopathic Arthritis In Long-Term Course Of Treatment With Tocilizumab

    Tomo Nozawa, Taichi Kanetaka, Kenichi Nishimura, Masako Kikuchi, Tomomi Sato, Nodoka Sakurai, Ryoki Hara, Kazuko Yamazaki and Shumpei Yokota, Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan

    Background/Purpose: Systemic-onset juvenile idiopathic arthritis (s-JIA) is a subtype of chronic childhood arthritis characterized by spiking fever, rash, and arthritis. Tocilizumab (TCZ), an anti-IL-6 receptor…
  • Abstract Number: 1143 • 2012 ACR/ARHP Annual Meeting

    Tocilizumab Therapy in Children with Systemic Onset Juvenile Idiopathic Arthritis. Russian Experience

    Ekaterina Alekseeva, Rina Denisova, Saniya Valieva, Tatyana Bzarova, Kseniya Isayeva, Alexandra Chomakhidze, Evgeniya Chistyakova, Tatyana Sleptsova and Elena Mitenko, Rheumatology, Scientific Center of Children's Health, Moscow, Russia

    Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is classified as an acquired autoinflammatory disease. The interleukin-1 and interleukin-6 play a pivotal role in pathogenesis of this…
  • Abstract Number: 1174 • 2012 ACR/ARHP Annual Meeting

    Severe Adverse Events Associated with Use of Biologic Therapy in Juvenile Idiopathic Arthritis: A Single-Center Study

    Ricardo A. G. Russo1 and Marìa M. Katsicas2, 1Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, 2Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina

    Background/Purpose: biologic agents have revolutionized the treatment of Juvenile Idiopathic Arthritis (JIA) and other conditions due to their high efficacy and safety. However, with the…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.